StudyFinder
KIN-1902-2001: A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis
Recruiting
We are studying a new medication, namilumab, given to treat Chronic Pulmonary Sarcoidosis. We are looking at the effectiveness, how well the drug is tolerated, and the side effects that occur. For the first part of the study, some people will receive the namilumab; the others will receive an inactive (placebo) drug. In the second part of the study, everyone may receive the namilumab.
18 years and over
Inclusion Criteria:
• Diagnosis of pulmonary sarcoidosis with some respiratory symptoms
• If receiving prednisone, must be on a stable dose of 25 mg or less for 4 weeks
• If receiving immunosuppressive therapy, must agree to stop if eligible to participate in the study
• Completion of primary series of COVID-19 vaccination
Exclusion Criteria:
• Pregnancy or breast-feeding
• Smoking or using any form of inhaled tobacco or cannabis within 6 months
Rare Diseases, Respiratory System
Clinics and Surgery Center (CSC), Sarcoidosis
UMN Sarcoidosis Research Group Study - umnsarc@umn.edu
Maneesh Bhargava
STUDY00014721
36882
See this study on ClinicalTrials.gov